The goal of this clinical trial is to evaluate the safety and tolerability of a single dose of ER-100 in adults with optic nerve conditions, specifically Open Angle Glaucoma (OAG) and Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION). The main questions it aims to answer are: * Is ER-100 safe when given as a single dose to people with OAG or NAION * What side effects may occur, if any, after taking ER-100? Participants will: * Receive a single dose of ER-100 * Undergo safety assessments including detailed eye examination and laboratory tests * Provide body fluid samples (tears, saliva, feces, urine) to help researchers understand how the drug is processed and cleared from the body * Complete questionnaires about their quality of life * Be followed for up to 5 years to monitor long-term health and vision outcomes
Age range
40 Years – 85 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
Incidence of Treatment-Emergent Adverse Events (TEAEs) During and Post-Doxycycline Activation Period
Timeframe: Baseline to Day 56, Day 112
Incidence of Dose-Limiting Toxicities During and Post-Doxycycline Activation Period
Timeframe: Baseline to Day 56, Day 112
Change in Safety Laboratory Tests (Liver Function Tests - LFTs) During and Post-Doxycycline Activation Period
Timeframe: Baseline to Day 56, Day 112
Change in Safety Laboratory Tests (Blood Protein Levels) During and Post-Doxycycline Activation Period
Timeframe: Baseline to Day 56, Day 112
Change in Safety Laboratory Tests (Calcium, Glucose, Bilirubin, Creatinine, Blood Urea Nitrogen) During and Post-Doxycycline Activation Period
Timeframe: Baseline to Day 56, Day 112
Change in Safety Laboratory Tests (Electrolytes: Sodium, Potassium, Chloride) During and Post-Doxycycline Activation Period
Timeframe: Baseline to Day 56, Day 112
Change in Safety Laboratory Tests (Electrolytes: Bicarbonate and Magnesium) During and Post-Doxycycline Activation Period
Timeframe: Baseline to Day 56, Day 112
Change in Safety Laboratory Tests (Hemoglobin) During and Post-Doxycycline Activation Period
Timeframe: Baseline to Day 56, Day 112
Change in Safety Laboratory Tests (Hematocrit) During and Post-Doxycycline Activation Period
Timeframe: Baseline to Day 56, Day 112
Change in Safety Laboratory Tests (White Blood Cell and Platelet Counts) During and Post-Doxycycline Activation Period
Timeframe: Baseline to Day 56, Day 112
Change in Safety Laboratory Tests (Red Blood Cell Count) During and Post-Doxycycline Activation Period
Timeframe: Baseline to Day 56, Day 112
Change in Safety Laboratory Tests (Erythrocyte Sedimentation Rate) During and Post-Doxycycline Activation Period
Timeframe: Baseline to Day 56, Day 112
Change in Safety Laboratory Tests (C-Reactive Protein) During and Post-Doxycycline Activation Period
Timeframe: Baseline to Day 56, Day 112
Change in Safety Laboratory Tests (Urine Test Results) During and Post-Doxycycline Activation Period
Timeframe: Baseline to Day 56, Day 112
Change from Baseline in the Intraocular Pressure (IOP) in the Treated Eye During and Post-Doxycycline Activation Period - Safety
Timeframe: Baseline to Day 56, Day 112
Change from Baseline in the Best Corrected Visual Acuity (BCVA) Letter Score in the Treated Eye During and Post-Doxycycline Activation Period - Safety
Timeframe: Baseline to Day 56, Day 112
Change from Baseline in Humphrey Visual Field (HVF) Test Results During and Post-Doxycycline Activation Period - Safety
Timeframe: Baseline to Day 56, Day 112
Change from Baseline in Pattern Electroretinogram (pERG) During and Post-Doxycycline Activation Period - Safety
Timeframe: Baseline to Day 56, Day 112
Change from Baseline in Quantitative Contrast Sensitivity Function (qCSF) During and Post-Doxycycline Activation Period - Safety
Timeframe: Baseline to Day 56, Day 112
Change from Baseline in Optical Coherence Tomography (OCT): Ganglion Cell Layer (GCL) Thickness During and Post-Doxycycline Activation Period - Safety
Timeframe: Baseline to Day 56, Day 112
Change from Baseline in Optical Coherence Tomography (OCT): Retinal Nerve Fiber Layer (RNFL) Thickness During and Post-Doxycycline Activation Period - Safety
Timeframe: Baseline to Day 56, Day 112
Change from Baseline in Slit Lamp Exam Results During and Post-Doxycycline Activation Period - Safety
Timeframe: Baseline to Day 56, Day 112